Navigation Links
First assessment of individual RLS domains in new post-hoc analyses of Neupro® studies
Date:4/25/2012

nd Communications, UCB
T +1.770.970.8352, andrea.levin@ucb.com     

Eimear O'Brien, Director, Brand Communications, UCB
T +32.2.559.9271, eimear.obrien@ucb.com

Antje Witte, Investor Relations, UCB
T +32.2.559.9414,
antje.witte@ucb.com

France Nivelle, Global Communications, UCB
T +32.2.559.9178,
france.nivelle@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such diff
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Genomic Health to Announce First Quarter 2012 Financial Results and Host Conference Call on Wednesday, May 2, 2012
3. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Henry Schein to Webcast First Quarter 2012 Conference Call Tuesday, May 8, at 10:00 a.m. EDT
6. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
7. Insmed to Host 2012 First Quarter Earnings Conference Call
8. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
9. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
10. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
11. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  Boston Scientific Corporation (NYSE: ... to purchase the Interventional business of Bayer AG. ... to offer physicians and healthcare systems a more ... conditions. The addition of the Bayer ... the Boston Scientific strategy to provide a comprehensive ...
(Date:9/2/2014)... , Sept. 2, 2014  Based on its ... device market, Frost & Sullivan recognizes Novian Health, ... Sullivan Award for Technology Innovation Leadership. Novian Health ... and malignant tumors with its proprietary technology, Novilase ... a reliable, accurate, and easy-to-control ultrasound-guided thermo ablation ...
(Date:9/2/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... consumables to the medical, research and veterinary markets, announced ... Executive Officer, will present at the Morgan Stanley Global ... a.m. ET. The conference will be held at the ... City . About Abaxis Abaxis develops, ...
Breaking Medicine Technology:Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2
... 1 Clinicians at Institut Catala d,Oncologia (ICO) in Barcelona ... RapidArc® radiotherapy from Varian Medical Systems (NYSE: VAR). A 73-year-old prostate cancer ... country to receive the fast and efficient treatment. , ... "The treatment went very well and the patient ...
... SAN DIEGO , June 1, 2010 Amylin Pharmaceuticals, ... , MD has been appointed Senior Vice President, Research and Development. ... Chief Medical Officer. These leadership changes will strengthen the Company,s focus ... its late-stage development programs, both important value drivers for the Company. ...
Cached Medicine Technology:Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 2Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 3Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 4Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development 2Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development 3Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development 4Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development 5
(Date:9/2/2014)... September 02, 2014 Eric Jimenez and ... Me , a revolutionary makeup application device. Designed to ... proven innovation in the palm of women’s hands to ... secret to Color Me’s success lies in its patented ... a rate of 15,000 pulses per minute, the device ...
(Date:9/2/2014)... NJ (PRWEB) September 02, 2014 BESLER ... protection services for hospitals, is pleased to announce that ... in-depth review of the FY 2015 Hospital Inpatient ... the Centers for Medicare & Medicaid Services. , “Hospitals ... variety of reasons,” said Jonathan Besler, BESLER’s President and ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 At the world-famous ... Lee has the unique distinction of being the first and ... history, Misty Lee is the first female magician to hold ... staff Medium at the Magic Castle,” says Misty Lee. “Even ... being at the Magic Castle, I can fascinate guests in ...
(Date:9/2/2014)... Request A Test , a leading national provider of direct to ... drug testing in September 2014. To take advantage of ... when placing their order. Request A Test offers a variety ... is typically done in panels which screen for multiple types of ... the 5 Panel Urine Screening and 10 Panel ...
(Date:9/2/2014)... 02, 2014 The Quantum Group, ... Quantum Innovations, Inc . (QI), it has submitted ... MU2 Certification with a private IT security laboratory approved ... The platform has Meaningful Use 1 certification status (see ... approved and 15 pending patents. The accrediting organization has ...
Breaking Medicine News(10 mins):Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3Health News:Magician Misty Lee is the First and Only Female Staff Medium at Hollywood’s Magic Castle 2Health News:Request A Test Offers 10% Off Drug Testing in September 2014 2Health News:Request A Test Offers 10% Off Drug Testing in September 2014 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 2Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 4Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 5
... who fear their own death say they are more prepared ... whom further medical treatment is considered futile,// reveals research published ... Archives of Disease in Childhood. ,The findings ... in the care of sick newborns (neonatologists) across Australia and ...
... low numbers of organ donors in Australia is an ongoing ... ,In the latest edition of the Medical Journal ... of the issues surrounding organ donation in Australia. ... the second the impact of public education campaigns on organ ...
... According to a latest Government data, there is an alarming ... this could be linked to the plummeting sale of// antidepressants. ... and Prevention (CDC) also indicated that youth in their late ... Food and Drug Administration had issued a black box warning ...
... using a sophisticated form of analysis called meta-analysis, in which ... for// possibly preventing up to half of the cases of ... in the United States. The work was conducted by a ... Center at University of California, San Diego (UCSD), and colleagues ...
... the United States and a growing epidemic worldwide. Now, ... able to make a valuable contribution to an overall ... ,A study published in the Journal of Vertebral ... when used as part of an integrative treatment in ...
... there is a pronounced increase of mental illnesses ... spectrum disorders, obsessive// compulsive disorders and hyperkinetic illnesses. ... Pediatric and Adolescent Medicine. ,Researches are ... to the increased awareness about these diseases or ...
Cached Medicine News:Health News:Doctors’ Own Fear of Death Linked to Hastening Death of Very Sick Newborn 2Health News:The Search for Organ Donors 2Health News:Two New Studies Back Vitamin D for Cancer Prevention 2Health News:Two New Studies Back Vitamin D for Cancer Prevention 3Health News:Research Explores Chiropractic's Effect on Diabetes 2
Liquichek Whole Blood Volatiles Control is an assayed liquid control for monitoring volatile compounds. This product is available in 2 levels....
qUAntify Control is designed to monitor the performance of urine dipstick testing. The control is available in 12 mL ready-to-use dropper bottles....
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
Lyphochek Tumor Marker Control is a comprehensive, bilevel product designed to assess the performance of various cancer antigen tests, including esoteric tumor markers....
Medicine Products: